Featured
A huge learning curve – my first week representing VIVA! as part of the GLOBALHealthPR Professional Exchange Program
As my first week representing VIVA! Communications, Australia as part of the GLOBALHealthPR Professional Exchange Program at Spectrum in Washington D.C. draws to a close, my head is spinning with all of the health PR-related information I’ve recently gleaned. This week I’ve participated in several interesting brainstorming sessions focusing on campaign concepts and new business…
Read MoreSydney’s third annual Recovery Walk – reducing the stigma of addiction & celebrating all forms of addiction recovery
The Sydney Recovery Walk, now in its third year since inception, is set for this Sunday, September 25. The free-to-all age event aims to end the stigma associated with addiction, and to celebrate all forms of recovery. Staged by Sydney Recovery and sponsored by CEO and founder of the Exodus Foundation, Rev. Bill Crews, the…
Read MoreWhat does the King Review mean for Pharmacy in Australia – August 5, 2016
Following the release of a discussion paper dubbed the “King Review” (as the Productivity Commission’s, Stephen King headed the review panel), which has been developed to review pharmacy remuneration and regulation procedures, discussions have opened up this week around what the review recommends and how this can impact pharmacy. The Federal Government and the Pharmacy…
Read MoreBREAKING NEWS: Chemmart & Terry White Merger anticipated end of October – August 4, 2016
This morning (August 4, 2016), EBOS Group Limited announced plans to merge its Chemmart business with the Terry White Group businesses, in order to create one of Australia’s largest retail pharmacy groups. In an EBOS investor release published today (August 4, 2016), the wholesaler announced the merge of Chemmart with Terry White would equate to…
Read MoreAustralia’s only locally manufactured QIV now TGA approved – August 2, 2016
Australia’s only locally manufactured, quadrivalent seasonal influenza vaccine (QIV) received Therapeutic Goods Administration (TGA) approval on July 15, 2016. Afluria Quad™, Seqirus’ four-strain, inactivated seasonal influenza vaccine, is indicated for people aged 18 years and older.1 The new quadrivalent vaccine will replace the company’s trivalent vaccine (TIV), Fluvax® for the 2017 flu season. Manufactured by…
Read More